The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
New Horizons in the Treatment of Osteosarcoma
Abstract
Osteosarcoma, which is most common in people 10 to 30 years of age, is generally treated with resection and adjuvant chemotherapy. Detection of gene rearrangements, copy-number variations, and targeted disruption of tumor suppressors by whole-genome sequencing has not yet led to improved treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients later diagnosed with osteosarcoma first seek medical care with concerns for persisting pain in an extremity 101 .”
From Osteosarcoma (2022) · cites this paper as [101]
Citations
Cites
1 retracted
RETRACTED: Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
Feng, W., Dean, D. C., Hornicek, F. J., Spentzos, D., Hoffman, R. M., Shi, H., & Duan, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922055 · Cited by 57
RetractedNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,531
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
A System for the Surgical Staging of Musculoskeletal Sarcoma
Enneking, W. F., Spanier, S. S., & GOODMAN, M. A. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198011000-00013 · Cited by 2,661
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Bielack, S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.776 · Cited by 2,391
Mutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
Cited by
Sorted by citations
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 428
Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics
Shi, P., Cheng, Z., Zhao, K., Chen, Y., Zhang, A., Gan, W., & Zhang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01826-1 · Cited by 216
Cillo, A. R., Mukherjee, E., Bailey, N. G., Onkar, S., Daley, J. D., Salgado, C. M., Li, X., Liu, D., Ranganathan, S., Burgess, M. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1471 · Cited by 95
A tumor microenvironment-based prognostic index for osteosarcoma
Wu, C., Gong, S., Duan, Y., Deng, C., Kallendrusch, S., Berninghausen, L. K., Osterhoff, G., & Schopow, N. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00917-3 · Cited by 94
Metadata
- Authors
- Meltzer, P. S., & Helman, L. J.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Meltzer, Paul S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-25
- Volume
- 385
- Issue
- 22
- Pages
- 2066-2076
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3217429854
- Cited by
- 672
- References
- 67
- Citations by year
- 2026: 123 · 2025: 173 · 2024: 156 · 2023: 143 · 2022: 74
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- osteosarcoma, gene rearrangement, copy number variation, tumor suppressor, targeted therapy, whole genome sequencing, adjuvant chemotherapy, pediatric bone tumors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Humans, Immunotherapy, Prognosis, Osteosarcoma, Survival Rate, Neoadjuvant Therapy, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
